Literature DB >> 12557148

Treatment of cirrhosis and liver failure in rats by hepatocyte xenotransplantation.

Hideo Nagata1, Masahiro Ito, Jin Cai, Albert S Edge, Jeffrey L Platt, Ira J Fox.   

Abstract

BACKGROUND & AIMS: Hepatocyte transplantation has been proposed as an alternative to liver transplantation for the treatment of hepatic failure. A major limitation to this form of therapy is the availability of human livers as a source of hepatocytes. The use of porcine hepatocytes might address this problem; however, xenogeneic hepatocytes are thought to be functionally incompatible across species and susceptible to irreversible rejection.
METHODS: Liver cirrhosis was induced with phenobarbital and carbon tetrachloride. Only rats with decompensated liver failure that did not correct 4 weeks after the discontinuation of carbon tetrachloride were subjected to intrasplenic rat or porcine hepatocyte transplantation. The immunologic integrity of cirrhotic rats was assessed by allogeneic skin grafting, and the immune response to transplanted porcine hepatocytes was assessed by enzyme-linked immunosorbent assay.
RESULTS: Porcine hepatocytes restored metabolic function and prolonged the survival of cirrhotic rats, as well as rat hepatocytes. Cirrhotic rats retained the ability to reject allogeneic skin grafts and showed an immune response to the engrafted hepatocytes. Despite this, survival of transplanted porcine hepatocytes was accepted in cirrhotic rats for a period of weeks without immunosuppression. Conventional immunosuppression with FK506 allowed successful retransplantation with hepatocytes from a second porcine donor.
CONCLUSIONS: Hepatocytes transplanted between widely divergent species can function to correct liver failure in cirrhotic rats and prolong their survival. Conventional immunosuppression allows long-term functioning of xenogeneic hepatocyte retransplants and suggests that hepatocyte xenotransplantation might be useful as a bridge to liver transplantation and could potentially provide long-term hepatic support.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12557148     DOI: 10.1053/gast.2003.50065

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  23 in total

Review 1.  Genetic modification of xenografts.

Authors:  J L Platt
Journal:  Curr Top Microbiol Immunol       Date:  2003       Impact factor: 4.291

2.  New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases.

Authors:  Jennifer R Ferrer; Attasit Chokechanachaisakul; Jason A Wertheim
Journal:  Curr Transplant Rep       Date:  2015-06-01

3.  The future of organ replacement: needs, potential applications, and obstacles to application.

Authors:  M Cascalho; J L Platt
Journal:  Transplant Proc       Date:  2006-03       Impact factor: 1.066

4.  Cell therapeutic options in liver diseases: cell types, medical devices and regulatory issues.

Authors:  Andreas K Nussler; Katrin Zeilinger; Lilianna Schyschka; Sabrina Ehnert; Jörg C Gerlach; Xueying Yan; Serene M L Lee; Maren Ilowski; Wolfgang E Thasler; Thomas S Weiss
Journal:  J Mater Sci Mater Med       Date:  2011-04-03       Impact factor: 3.896

5.  Expression, purification and bioactivity of human augmenter of liver regeneration.

Authors:  Yang-De Zhang; Jian Zhou; Jin-Feng Zhao; Jian Peng; Xiao-Dong Liu; Xin-Sheng Liu; Ze-Ming Jia
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

Review 6.  Noncognate function of B cells in transplantation.

Authors:  Samuel J Balin; Jeffrey L Platt; Marilia Cascalho
Journal:  Transpl Int       Date:  2009-01-16       Impact factor: 3.782

Review 7.  The role of antibodies in transplantation.

Authors:  Alexander T Chang; Jeffrey L Platt
Journal:  Transplant Rev (Orlando)       Date:  2009-07-22       Impact factor: 3.943

Review 8.  Clinical application of bioartificial liver support systems.

Authors:  Maarten Paul van de Kerkhove; Ruurdtje Hoekstra; Robert A F M Chamuleau; Thomas M van Gulik
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

9.  Lack of CD47 on donor hepatocytes promotes innate immune cell activation and graft loss: a potential barrier to hepatocyte xenotransplantation.

Authors:  Nalu Navarro-Alvarez; Yong-Guang Yang
Journal:  Cell Transplant       Date:  2013-02-07       Impact factor: 4.064

Review 10.  Liver cirrhosis.

Authors:  Detlef Schuppan; Nezam H Afdhal
Journal:  Lancet       Date:  2008-03-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.